BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33652766)

  • 1. Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine.
    Visser N; Lourens HJ; Huls G; Bremer E; Wiersma VR
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33652766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance.
    Cheong JW; Kim Y; Eom JI; Jeung HK; Min YH
    Mol Med Rep; 2016 Apr; 13(4):3433-40. PubMed ID: 26935591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine‑induced death of leukaemia cells.
    Palmeira dos Santos C; Pereira GJ; Barbosa CM; Jurkiewicz A; Smaili SS; Bincoletto C
    J Cancer Res Clin Oncol; 2014 Jun; 140(6):909-20. PubMed ID: 24659340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
    Chromik J; Safferthal C; Serve H; Fulda S
    Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling.
    Su Q; Huang P; Luo X; Zhang P; Li H; Chen Y
    Hematology; 2023 Dec; 28(1):2255802. PubMed ID: 37815490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
    Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
    Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
    Sumitomo Y; Koya J; Nakazaki K; Kataoka K; Tsuruta-Kishino T; Morita K; Sato T; Kurokawa M
    Blood; 2016 Sep; 128(12):1614-24. PubMed ID: 27480114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.
    Wang HL; Li JN; Kan WJ; Xu GY; Luo GH; Song N; Wu WB; Feng B; Fu JF; Tu YT; Liu MM; Xu R; Zhou YB; Wei G; Li J
    Acta Pharmacol Sin; 2023 Nov; 44(11):2296-2306. PubMed ID: 37316630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
    Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
    Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
    Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
    Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.
    Wang X; Harrison JS; Studzinski GP
    J Steroid Biochem Mol Biol; 2016 Nov; 164():72-78. PubMed ID: 26319201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.
    Kim Y; Eom JI; Jeung HK; Jang JE; Kim JS; Cheong JW; Kim YS; Min YH
    Biomed Pharmacother; 2015 Jul; 73():87-96. PubMed ID: 26211587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity.
    Zheng R; Studzinski GP
    J Cell Biochem; 2017 Jun; 118(6):1583-1589. PubMed ID: 27922189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
    Kim JH; Lee C; Cheong HS; Koh Y; Ahn KS; Kim HL; Shin HD; Yoon SS
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):533-40. PubMed ID: 27422302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.
    Ogbomo H; Michaelis M; Klassert D; Doerr HW; Cinatl J
    Neoplasia; 2008 Dec; 10(12):1402-10. PubMed ID: 19048119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance.
    Choukrani G; Visser N; Ustyanovska Avtenyuk N; Olthuis M; Marsman G; Ammatuna E; Lourens HJ; Niki T; Huls G; Bremer E; Wiersma VR
    Cell Death Discov; 2023 Jul; 9(1):228. PubMed ID: 37407572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.
    Spinello I; Saulle E; Quaranta MT; Pasquini L; Pelosi E; Castelli G; Ottone T; Voso MT; Testa U; Labbaye C
    Haematologica; 2019 May; 104(5):973-985. PubMed ID: 30467201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
    Bosc C; Saland E; Bousard A; Gadaud N; Sabatier M; Cognet G; Farge T; Boet E; Gotanègre M; Aroua N; Mouchel PL; Polley N; Larrue C; Kaphan E; Picard M; Sahal A; Jarrou L; Tosolini M; Rambow F; Cabon F; Nicot N; Poillet-Perez L; Wang Y; Su X; Fovez Q; Kluza J; Argüello RJ; Mazzotti C; Avet-Loiseau H; Vergez F; Tamburini J; Fournié JJ; Tiong IS; Wei AH; Kaoma T; Marine JC; Récher C; Stuani L; Joffre C; Sarry JE
    Nat Cancer; 2021 Nov; 2(11):1204-1223. PubMed ID: 35122057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.
    Illangeswaran RSS; Jebanesan DZP; Sivakumar KK; Vidhyadharan RT; Rajamani BM; Janet NB; David E; Velayudhan SR; Mathews V; Balasubramanian P
    Leuk Res; 2023 May; 128():107054. PubMed ID: 36906941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.